Abivax reports promising ABX464 phase 2a one-year maintenance results in rheumatoid arthritis
DGAP-News: ABIVAX / Key word(s): Study results10.03.2022 / 08:00 The issuer is solely responsible for the content of this announcement.Abivax reports promising ABX464 phase 2a one-year maintenance results in rheumatoid arthritis Out of the 40 patients who enrolled into the ABX464 maintenance study, 23 patients have...